VCM
MBX

Versant Capital Management’s MBX Biosciences MBX Stock Holding History

Versant Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24
Closed -$716 – 2866
2026
Q1 		$716 Buy
+24
New +$816 ﹤0.01% 2690

Other funds holding MBX

AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
KWM
Koa Wealth Management Encinitas, California $147M AUM 18.41% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
GIM
Goelzer Investment Management Carmel, Indiana $2.29B AUM 39.12% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

Versant Capital Management's MBX Position: Q2 2026 in Review

Versant Capital Management sold out of MBX Biosciences (MBX) in Q2 2026, closing a stake of 24 shares — an estimated $716 sold.

Versant Capital Management first reported a position in MBX in Q1 2026 and held it in 1 quarter. The position peaked at $716 in Q1 2026. 13 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Versant Capital Management reported no remaining MBX Biosciences position as of Q2 2026 after selling out during the quarter.
  • Versant Capital Management sold 24 MBX Biosciences shares in Q2 2026, an estimated $716.
  • Versant Capital Management first reported a position in MBX Biosciences in Q1 2026 and held it in 1 quarter.
  • Versant Capital Management's MBX Biosciences position peaked at $716 in Q1 2026.
  • 13 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.